Kestra Medical Technologies (KMTS) Depreciation & Amortization (CF) (2024 - 2026)

Kestra Medical Technologies (KMTS) has 3 years of Depreciation & Amortization (CF) data on file, last reported at $2.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $2.0 million, up 5.03% year-over-year; the trailing twelve-month figure through Jan 2026 was $8.2 million (down 14.68% YoY), and the FY2025 annual result was $8.0 million, down 31.07% from the prior year.
• Depreciation & Amortization (CF) retreated to $2.0 million in Q1 2026 per KMTS's latest filing, from $2.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $3.5 million in Q2 2024 and troughed at $1.8 million in Q2 2025.
• A 3-year average of $2.4 million and a median of $2.0 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• On a YoY basis, Depreciation & Amortization (CF) climbed as much as 26.97% in 2025 and fell as far as 47.57% in 2025.
• A 3-year view of Depreciation & Amortization (CF) shows it stood at $1.9 million in 2024, then rose by 26.97% to $2.4 million in 2025, then slipped by 16.43% to $2.0 million in 2026.
• Business Quant data shows KMTS's Depreciation & Amortization (CF) at $2.0 million in Q1 2026, $2.4 million in Q4 2025, and $2.0 million in Q3 2025.